Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003382 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer
A Phase 1 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00003382: Clinical Trial Phase 1 study, sponsored by Gynecologic Oncology Group.
NCT00003382 is a Phase 1 study that was terminated before completion, run by Gynecologic Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003382, a Phase 1 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy consisting of gemcitabine and topotecan in treating patients with refractory or recurrent ovarian or fallopian tube cancer.
Interventions
- BIOLOGICAL filgrastim
- DRUG gemcitabine hydrochloride
- DRUG topotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-05 |
| Phase | Phase 1 |
Why NCT00003382 stopped before completion
NCT00003382 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which filgrastim is the first listed.
NCT00003382 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003382 about?
NCT00003382 is a clinical study titled "Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy consisting of gemcitabine and topotecan in tr...
What is the current status of trial NCT00003382?
This trial is currently terminated. It is a Phase 1 study. The study started on 1998-05.
What interventions are being tested in trial NCT00003382?
The interventions under investigation include: filgrastim (BIOLOGICAL), gemcitabine hydrochloride (DRUG), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003382?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia